These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2936 related items for PubMed ID: 25092394

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis.
    Sindet-Pedersen C, Pallisgaard JL, Olesen JB, Gislason GH, Arevalo LC.
    Thromb Res; 2015 Oct; 136(4):732-8. PubMed ID: 26277682
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
    Wang X, Ma Y, Hui X, Li M, Li J, Tian J, Wang Q, Yan P, Li J, Xie P, Yang K, Yao L.
    Cochrane Database Syst Rev; 2023 Apr 14; 4(4):CD010956. PubMed ID: 37058421
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.
    Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF.
    Thromb Haemost; 2018 Sep 14; 118(9):1637-1645. PubMed ID: 30103250
    [Abstract] [Full Text] [Related]

  • 28. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, Mu Q, Mardekian J, Russ C, Okano GJ, Rosenblatt L.
    J Manag Care Spec Pharm; 2020 Aug 14; 26(8):1017-1026. PubMed ID: 32452277
    [Abstract] [Full Text] [Related]

  • 29. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
    Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, Alonso A.
    Blood Adv; 2018 Feb 13; 2(3):200-209. PubMed ID: 29378726
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC, Turpie AG.
    Curr Med Res Opin; 2013 Jul 13; 29(7):783-90. PubMed ID: 23659584
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Apixaban: A Review in Venous Thromboembolism.
    Greig SL, Garnock-Jones KP.
    Drugs; 2016 Oct 13; 76(15):1493-1504. PubMed ID: 27653758
    [Abstract] [Full Text] [Related]

  • 40. Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy.
    Shyu M, Liu A, Srikureja A, Gregorian A, Srisuwananukorn A, Tremblay D, Naymagon L.
    J Thromb Thrombolysis; 2024 Jun 13; 57(5):871-876. PubMed ID: 38643437
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 147.